Mechanism of Drug-Eluting Absorbable Metal Scaffold Restenosis: A Serial Optical Coherence Tomography Study.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
03 2020
Historique:
entrez: 26 2 2020
pubmed: 26 2 2020
medline: 11 11 2020
Statut: ppublish

Résumé

The pathomechanisms underlying restenosis of the bioabsorbable sirolimus-eluting metallic scaffold (Magmaris) remain unknown. Using serial optical coherence tomography, we investigated causes of restenosis, including the contribution of late scaffold recoil versus neointimal hyperplasia. Patients enrolled in BIOSOLVE-II undergoing serial angiography and optical coherence tomography (post-intervention and follow-up: 6 months and/or 1 year) were analyzed. Patients were divided into 2 groups according to angiographic in-scaffold late lumen loss (LLL) <0.5 or ≥0.5 mm. End points were late absolute scaffold recoil and neointimal hyperplasia area as assessed by optical coherence tomography. Serial data were available for analysis from 70 patients (LLL <0.5 mm: n=41; LLL ≥0.5 mm: n=29). Patient and lesion characteristics were comparable, and there was no significant difference in mean and minimal scaffold area between groups at post-intervention. Late absolute scaffold recoil was less among patients with LLL <0.5 mm (0.53±0.68 mm In addition to neointimal hyperplasia, late scaffold recoil contributed significantly to LLL of sirolimus-eluting absorbable metal scaffolds. The extent of late scaffold recoil was dependent on the underlying plaque morphology and was the highest among fibrotic lesions. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01960504.

Sections du résumé

BACKGROUND
The pathomechanisms underlying restenosis of the bioabsorbable sirolimus-eluting metallic scaffold (Magmaris) remain unknown. Using serial optical coherence tomography, we investigated causes of restenosis, including the contribution of late scaffold recoil versus neointimal hyperplasia.
METHODS
Patients enrolled in BIOSOLVE-II undergoing serial angiography and optical coherence tomography (post-intervention and follow-up: 6 months and/or 1 year) were analyzed. Patients were divided into 2 groups according to angiographic in-scaffold late lumen loss (LLL) <0.5 or ≥0.5 mm. End points were late absolute scaffold recoil and neointimal hyperplasia area as assessed by optical coherence tomography.
RESULTS
Serial data were available for analysis from 70 patients (LLL <0.5 mm: n=41; LLL ≥0.5 mm: n=29). Patient and lesion characteristics were comparable, and there was no significant difference in mean and minimal scaffold area between groups at post-intervention. Late absolute scaffold recoil was less among patients with LLL <0.5 mm (0.53±0.68 mm
CONCLUSIONS
In addition to neointimal hyperplasia, late scaffold recoil contributed significantly to LLL of sirolimus-eluting absorbable metal scaffolds. The extent of late scaffold recoil was dependent on the underlying plaque morphology and was the highest among fibrotic lesions. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01960504.

Identifiants

pubmed: 32093514
doi: 10.1161/CIRCINTERVENTIONS.119.008657
doi:

Substances chimiques

Cardiovascular Agents 0
Metals 0
Sirolimus W36ZG6FT64

Banques de données

ClinicalTrials.gov
['NCT01960504', 'NCT01960504']

Types de publication

Clinical Trial Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e008657

Auteurs

Yasushi Ueki (Y)

Department of Cardiology, Bern University Hospital, Switzerland (Y.U., L.R., T.O., S.W.).

Lorenz Räber (L)

Department of Cardiology, Bern University Hospital, Switzerland (Y.U., L.R., T.O., S.W.).

Tatsuhiko Otsuka (T)

Department of Cardiology, Bern University Hospital, Switzerland (Y.U., L.R., T.O., S.W.).

Himanshu Rai (H)

Deutsches Herzzentrum München, Technische Universität München, Germany (H.R., R.B., M.J.).

Sylvain Losdat (S)

Institute of Social and Preventive Medicine and Clinical Trials Unit, University of Bern, Switzerland (S.L.).

Stephan Windecker (S)

Department of Cardiology, Bern University Hospital, Switzerland (Y.U., L.R., T.O., S.W.).

Hector M Garcia-Garcia (HM)

Section of Interventional Cardiology, Medstar Washington Hospital Center, DC (H.M.G.-G.).

Ulf Landmesser (U)

Department of Cardiology, Charite Universitätsmedizin Berlin, Germany (U.L.).

Jacques Koolen (J)

Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands (J.K.).

Robert Byrne (R)

Deutsches Herzzentrum München, Technische Universität München, Germany (H.R., R.B., M.J.).

Michael Haude (M)

Medical Clinic I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Germany (M.H.).

Michael Joner (M)

Deutsches Herzzentrum München, Technische Universität München, Germany (H.R., R.B., M.J.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH